biotech
Anti-Depression Transdermal Patch Approved by FDA
Filed in archive Drugs, Vaccines and Therapeutics by ruth on March 8, 2006
Anti-Depression Transdermal Patch Approved by FDA
After more than a decade of testing, the US FDA last week approved the antidepressant patch, Emsam, produced by Somerset Pharmaceuticals. Bristol-Myers Squibb will market the patch in the US, where 14 million adults could become candidates for the drug.

Emsam is a monoamine oxidase inhibitor, which, when taken orally, can react with foods such as cheese and processed meats, raising blood pressure. The transdermal patch circumvents this side-effect, and has been shown in clinical trials to be able to relieve depression without having to modify the patient's diet.

"Clinicians who have used these drugs always felt that they were more effective than other antidepressants, but we've been limited in using them," said Dr. Robert Hirschfeld, chairman of the department of psychiatry at the University of Texas Medical Branch in Galveston. "To have a new way to utilize this medicine is a terrific step forward."


Read full story from the Baltimore Sun and more about the Emsam patch on BestSyndication.

Permalink: Anti-Depression Transdermal Patch Approved by FDA
Tags: depression  patch  biotech  approved  transdermal  transdermal+patch  anti+depression  patch+approved 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/17803
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Anti-Depression Transdermal Patch Approved by FDA:

  • Currently 6.80/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 6.80 out of 5 vote(s) cast.
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!